Sridhar Ramaswamy
Venture Partner at GV
Boston, Massachusetts
Overview
Work Experience
Venture Partner
2021 - Current
Investing in early-stage life science companies • Leyden Labs, Board Observer (2021-present) • Invetx, Board Observer (2022-24 / M&A 2024) • Invivyd, Board Observer (2020-21 / IPO 2021)
Entrepreneur In Residence
2019
Biotech company creation • Q1, Inc., Founder & CEO (2020-present) • Q2, Inc., Founder & CEO (2023-present)
Guest Lecturer
2019
• Massachusetts Institute of Technology • Broad Institute of Harvard & MIT • Harvard Business School
Google Ventures is an investment arm of Alphabet that provides seed, venture, and growth-stage funding to technology companies.
Scientific Advisory Board
2018
Senior Vice President & Head, R&D
2016 - 2019
Research & Development, Cancer Therapeutics, Executive Leadership • Built and led a matrix team of 70 drug discovery, translational, and development experts that worked closely with BD, CMC, medical, regulatory, and commercial strategy groups to enable the integrated and externalized discovery, development, and commercialization of a cancer and immuno-oncology pipeline • Directed early pipeline creation through discovery, acquisition, and partnership; early development of new therapeutics from concept through first-in-man studies; and translational science to best position our drugs at the right dose, schedule, and cancer indications so patients most likely benefit • Contributed to small-molecule and antibody discovery, early development, translational biomarker identification & strategy, clinical development & regulatory approval, and commercialization of 11 cancer drugs including niraparib (PARP1/2), dostarlimab (PD1), cobolimab (TIM3), and rolapitant (NK1) for patients with ovarian, prostate, uterine, rectal and other solid tumors • Represented R&D externally with the scientific, medical, regulatory, commercial, and investor communities • Served as a key member of the executive leadership team that led TESARO as a publicly traded, oncology-focused, global biopharmaceutical company and spearheaded its successful acquisition and integration by GSK for $5.1B
TESARO is an oncology-focused biopharmaceutical company identifying better cancer therapies to improve the lives of patients with cancer.
Raised $1,095,699,915.00 from Ally Bridge Group, Johnson & Johnson, InterWest Partners, New Enterprise Associates, Kleiner Perkins and Future Fund.
Associate Professor of Medicine
2001 - 2019
Medical Oncology & Hematology, Translational & Basic Research, Teaching & Administration • Directed the highly-specialized, multidisciplinary care for patients with breast, GI, and hematologic cancers in both the inpatient and outpatient settings at the Massachusetts General Hospital, Brigham & Women's Hospital, and Dana-Farber Cancer Institute • Founded and directed a highly-influential, NIH-funded, multidisciplinary research program focused on understanding how human carcinomas grow and progress from localized cancers, via circulating tumors cells, into advanced, metastatic, dormant, and treatment-resistant disease (h-index = 73) • Developed cancer systems biology approaches to study human tumors as complex, adaptive, multi-scale systems • Disseminated many tools, methods, and approaches invented by my research group to the worldwide cancer research, translational medicine, and drug development communities • Taught a generation of medical & graduate students, interns & residents, and clinical & research fellows in the classroom, at the bench, and the bedside.
MGH / Samana Cay Endowed Investigator
2015 - 2017
Cancer Biology & Therapeutics, Translational & Basic Research, Teaching, Administration
Director, Center for Computational Biology
2004 - 2017
Integrative, Systems, & Computational Biology, Bioinformatics, Data Science
Tucker Gosnell Investigator
2004 - 2017
Medical Oncology, Cancer Biology & Therapeutics, Translational & Basic Research, Teaching, Administration
Principal Investigator, Center for Cancer Research
2004 - 2017
Patient-oriented laboratory research
Attending Physician in Medicine & Cancer Center
2000 - 2017
Medical Oncology, Hematology, Internal Medicine
Associate Member
2006 - 2017
Genetics & Genomics, Systems Biology, Data Science
Principal Member
2006 - 2017
Stem Cell Biology, Regenerative Medicine
Harvard Stem Cell Institute is a a community of scientists in stem cell science seeking to bring new treatments and new life to patients.
Associate Member
2006 - 2017
Cancer Biology, Cancer Therapeutics & Diagnostics
Ludwig Cancer Research is a global community of leading scientists pursuing innovative ways to prevent and control cancer.
Attending Physician in Medicine
2001 - 2004
Medical Oncology, Therapeutics, & Diagnostics, Translational & Basic Research, Cancer Biology, Teaching
Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
Raised $67,079,019.00 from Llama, Hyundai Hope On Wheels, Hyundai Hope On Wheels, Break Through Cancer, Paula and Rodger Riney Foundation, Massachusetts Life Sciences Center and Massachusetts Life Sciences Center.
Attending Physician in Medicine
2001 - 2004
Medical Oncology, Therapeutics, & Diagnostics, Translational & Basic Research, Cancer Biology, Teaching